Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study is a randomized, non-blinded clinical trial specifically designed to assess the initial feasibility and efficacy of SGLT2 inhibitors in treating NAFLD among adults diagnosed with type 2 diabetes.